Addex Therapeutics (ADXN) Total Non-Current Liabilities (2018 - 2026)
Addex Therapeutics (ADXN) posted Total Non-Current Liabilities of $319675.1 for Q1 2026, down 35.9% sequentially from $498736.3 in Q4 2025, and up 117.47% YoY from $146999.5 in Q1 2025.
Addex Therapeutics (ADXN) Total Non-Current Liabilities (2018 - 2026) Analysis & Trends
Addex Therapeutics has reported Total Non-Current Liabilities for 9 years, with the latest figure at $319675.1 in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 117.47% year-over-year to $319675.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $319675.1 (up 117.47% YoY) and the FY2025 annual result came in at $480782.1, up 112.61% from the prior year.
- Total Non-Current Liabilities slipped to $319675.1 in Q1 2026 per ADXN's latest filing, from $498736.3 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $815918.9 in Q1 2022 and troughed at $39280.8 in Q1 2023.
- A 5-year average of $266950.3 and a median of $227093.2 in 2024 frame the typical range for Total Non-Current Liabilities.
- The widest YoY moves for Total Non-Current Liabilities: up 652.68% in 2023, down 95.19% in 2023.
- Over 5 years, Total Non-Current Liabilities stood at $90337.0 in 2022, then soared by 652.68% to $679948.1 in 2023, then tumbled by 66.6% to $227093.2 in 2024, then soared by 119.62% to $498736.3 in 2025, then plunged by 35.9% to $319675.1 in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $319675.1, $498736.3, and $246706.6 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Addex Therapeutics | 534.71 Mn | 534.71 Mn | - | 319,675.14 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 319,675.14 |
| Dec 31, 2025 | 498,736.30 |
| Sep 30, 2025 | 246,706.61 |
| Jun 30, 2025 | 172,538.66 |
| Mar 31, 2025 | 146,999.48 |
| Dec 31, 2024 | 227,093.21 |
| Sep 30, 2024 | 252,155.04 |
| Jun 30, 2024 | 113,789.47 |
| Mar 31, 2024 | 62,416.77 |
| Dec 31, 2023 | 679,948.07 |
| Sep 30, 2023 | 297,382.51 |
| Jun 30, 2023 | 176,277.60 |
| Mar 31, 2023 | 39,280.80 |
| Dec 31, 2022 | 90,336.97 |
| Sep 30, 2022 | 166,899.04 |
| Jun 30, 2022 | 232,001.38 |
| Mar 31, 2022 | 815,918.85 |
| Dec 31, 2021 | 1.60 Mn |
| Sep 30, 2021 | 1.58 Mn |
| Jun 30, 2021 | 1.56 Mn |